Other adverse events included infections (23%), immune effector cell-associated neurotoxicity syndrome (ICANS, 13%), and kidney injury (13%).<h4>Conclusion</h4>Dual-target CD38/BCMA CAR-T demonstrates promising efficacy and manageable safety in RRMM. This evidence concerns the gene CD38 and infection.